Ketamine molecule:

Image from PubChem

Ketamine Clinical Trials


NRX-101 for Maintenance of Remission From Severe Bipolar Depression in Patients With Acute Suicidal Ideation and Behavior: The SBD-ASIB Study


To see complete record on clinicaltrials.gov, please visit this link

Id: NCT03396068

Organisation Name: NeuroRx, Inc.

Overal Status: Recruiting

Start Date: December 1, 2019

Last Update: November 2, 2020

Lead Sponsor: NeuroRx, Inc.

Brief Summary: NMDA antagonist drugs have increasingly been demonstrated to reduce symptoms of depression and suicidal ideation. NeuroRx has developed a sequential therapy consisting of IV NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. NRX-101 has been awarded Fast Track and Breakthrough Therapy Designation by the US Food and Drug Administration. The SevereBD study will test the hypothesis that NRX-101 is superior to lurasidone alone in maintaining remission from symptoms of depression (primary endpoint), clinical relapse (declared secondary endpoint), and suicidal ideation or behavior (declared secondary endpoint) over a six week period of twice-daily oral dosing.

Conditions:
  • Bipolar Depression
  • Suicidal Ideation


Total execution time in seconds: 0.18181085586548